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Abstract
Background: To evaluate efficacy and feasibility of chemo-radiotherapy in patients with non-metastatic anal
squamous-cell-cancer.
Methods: TNM staged anal squamous-cell cancer patients were treated with pelvic radiotherapy concomitant to
continuous infusion fluorouracil plus cisplatin for at least 2 cycles. In T3-T4 or any T - N+ tumours or in “slow-
responder” cases, 1-2 chemotherapy courses were subsequently administered. Tumour assessment was performed
at baseline and 6-8 weeks after radiotherapy to evaluate response.
Results: 29 patients were enrolled: 4 males, 25 females; median age 57 years; baseline T1/T2/T3/T4 2/12/7/8; N
involvement 17. Median dose pelvic radiotherapy was 59.4 Gy (range: 54-74). In 5 patients 2 chemotherapy
courses, in 12 patients three and in 12 patients four courses were performed. At first evaluation, 27 CR (93.1%;
95% CI: 78% - 98%) and 2 SD were observed. Main grade (G) 3 toxic events were neutropenia (8%), diarrhoea
(8%) and dermatitis (62%). Most frequent late events G3-G4 occurred in 14 patients: proctitis (5), dermatitis (4),
bladder dysfunctions (2), sexual dysfunctions (9), lower extremity venous thromboses (2), dysuria (1), stenosis (1)
and tenesmus (1). Five patients reported G1 leucopoenia. The rate of colostomy was 14%. After a median follow
up of 42 months (range: 4-81), 20 patients are still alive without relapse and 3 died due to PD. The estimated
7-year DFS was 83.4% (C.I.: 68.3%-98.5%) and the estimated 7-year OS was 85.7% (C.I.: 70% - 100%). The 1-year
and the estimated 7-year colostomy-free survivals were 85.9% (C.I.: 73.1% - 98.7%).
Conclusions: Concurrent cisplatin plus fluorouracil and radiotherapy is associated with favourable local control
rates and acute toxicity. Future investigations will be directed towards research into molecular biomarkers related
to disease progression and resistance to chemo-radiotherapy and to the evaluation of new cytotoxic agents or
targeted drugs, such as anti-epidermal growth factor receptor, concomitant to RT and to determining the role of
intensity-modulated radiotherapy.
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Anal carcinoma is an uncommon disease that represents
approximately 1% of all gastrointestinal malignancies
with increasing incidence over the past 25 years. Risk
factors include HPV-infection, immune depression-
suppression, and smoking. Loco-regional progression
often occurs while metastatic potential is present in 15%
of patients [1]. Localized stage and a radio-chemothera-
peutic sensitive tumour represent favourable conditions
suitable to curative non-surgical treatment. The conven-
tional approach with external-beam radiation therapy
(RT) with concomitant fluorouracil (FU) and mitomycin
(M) has induced successful disease control in two thirds
of patients [2]. An anal lesion size greater than 5 cm
and regional node involvement are two clinical features
that have resulted in a reduction of the cure rate (local
control 50-60%) and worst outcome; a more aggressive
approach is needed in this setting of patients [3]. With
the aim of increasing objective response and reducing
haematologic toxicity related to M, cisplatin (C) was
investigated in clinical trials, due to its property as
radiation sensitizer and its therapeutic potential in squa-
mocellular histology, and the interesting results also
seen in anal cancer. But the optimal duration and the
best chemotherapy-combination containing C, have not
been yet determined. Our mono-institutional phase II
trial aimed to evaluate FU as continuous infusion (c.i.)
plus C in patients affected by non-metastatic anal squa-
mous cell cancer (SCC) with primary tumours larger
than 2 cm. The number of cycles was tailored on base-
line patients characteristics and tumour response at the
end of RT: one or two additional courses after RT were
planned in high risk patients with T >5 cm and/or
node-positive disease at baseline or in cases of persis-
tence of primary lesion with regression <50% (slow
responders) at the end of RT. The rationale of such a
strategy was justified by early use of radiotherapy com-
bined with radiosensitive agents and also in order to
evaluate the role of systemic therapy if administered
after the end of radiotherapy.
Primary goals were complete remission (CR) and dis-
ease-free survival (DFS) and secondary aims were colost-
omy rate and overall survival (OS).
Methods
Patients and inclusion criteria
We undertook a prospective study with chemo-radio-
therapy, in patients affected by T2-T4 anal carcinoma or
any T with locoregional positive nodes. Eligibility
criteria included: histologically proven anal squamous
cell carcinoma, age ≥ 18 years, ECOG performance sta-
tus ≤ 2, adequate haematological, liver and renal func-
tion (granulocyte count >1500/mm
3, platelet count
>100000/mm
3, haemoglobin >10 g/dl, serum creatinine
<1,25 Upper Limit of Normal (ULN), serum bilirubin
< 1 , 2 5U L N ,G O To rG P T< 2U L N ) ,a b s e n c eo fm e t a s -
tases, no prior systemic chemotherapy (CT) or RT to
the pelvis, life expectancy ≥ 3 months. Patients affected
by uncompensated cardiopathy or recent acute myocar-
dial infarction, peripheral neuropathy, uncontrolled
infection, inflammatory bowel disease or history of
another tumour, were excluded. Initial clinical work-up
was performed with a digital examination of the anus,
rectal wall and recto-vaginal septum, ano-rectal endo-
scopy and tumor biopsy, chest-abdomino-pelvic CT
scan, routine blood tests. The clinical T-stage and nodal
involvement were determined by anorectal endoscopic
ultrasound (EUS) or by pelvic MRI. Patients with
obstructive lesion underwent temporary colostomy
before commencement of the study. In all patients a
central vein catheter was positioned for chemotherapy
delivery. All patients signed a clinical trial informed con-
sent form that was notified to the European Institute of
Oncology Ethical Committee.
Treatment protocol
Radical radiotherapy was delivered by using a high
energy linear accelerator (≥15 MV or mixed energy).
Customized blocking for conformal techniques and
immobilization system were used in all cases. The gross
tumor volume (GTV), clinical target volume (CTV) and
planning target volume (PTV) and organs at risk
(OARS) were contoured using an Eclipse treatment
planning system (Varian Medical Systems, Palo Alto Ca,
USA). GTV included the primary tumor and any
involved lymph nodes. Two CTVs were considered: a
CTV1 which included the GTV, anal canal and a uni-
form margin of 1 cm; and a CTV2 which included
regional lymph nodes at risk such as the external iliac,
internal iliac, perirectal, obturator, presacral and the
inguinal lymph nodes. PTV 1 and PTV2 were generated
by adding a uniform 1.5 cm margin around the CTV1
and CTV2.
PTV2 is treated up to 36 Gy, 1.8 Gy per fraction, in
22 fractions with anterior and posterior (AP/PA) oppos-
ing fields with the superior border of the field at L5/S1
interspace and in nodal positive patients up to 45 Gy in
25 fractions of 1.8 Gy with the superior field lowered to
the bottom of the sacroiliac joints using either AP/PA
fields or a box-technique.
The planning goals were to deliver to the PTV1,
via external beam radiotherapy, a dose ranging from a
minimum of 41.4 Gy in case of T1-T2 tumors to a max-
imum of 59.4 in 1.8 Gy per fraction, by using multiple-
field technique. Brachytherapy (BRT) was allowed to be
administered to the primary tumor either in T1-T2
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Page 2 of 9patients in order to spare OARs after PTV2 phase com-
pletion or in T3 patients with a slow tumor response
after the maximum prescription external dose of
59.4 Gy. The large variability in dose prescription and in
administration modality reflected the different physi-
cians’ attitudes and any eventual treatment adjustment
in accordance with patient compliance.
Concurrent chemotherapy containing FU 200 mg/m2
i.v. daily as 24 hours continuous infusion administered
via a portable pump through central vein port-a-cath
a n da tl e a s t2c y c l e so fC8 0m g / m 2d a y s1 ; 2 1i vw e r e
planned in an outpatient setting. One course
was defined as one administration of C plus 3 weeks of
c.i. FU.
In patients with T3-T4 or nodal involvement at base-
line work-up or in “slow-responder” cases (persistence
of local disease with regression <50%) evaluated by at
least two physicians at the end of RT, 2 chemotherapy
courses were considered. After 6 and within 8 weeks
after concomitant chemoradiotherapy, patients under-
went tumour reassessment with clinical and instrumen-
tal evaluation with ano-rectal EUS and/or pelvic MRI.
Tumoral biopses were planned only in case of suspi-
cious progressive local disease. Subsequent tumour eva-
luation in non-progressive cases was repeated every
3 months for the first 2 years and every 6 months there-
after. Chest and abdominal CT scan was performed
every 6 months for 2 years and every 12 months
thereafter.
Statistical design
Response was evaluated according to Word Health
Organization (WHO) criteria [4]. Acute toxicity was
assessed using the National Cancer Institute Common
Toxicity Criteria (NCI-CTC) scale, version 2.0, com-
bined to Radiation Therapy Oncology Group (RTOG)
scale; late toxicity using SOMA-LENT scale. Treatment
was delayed for toxicity G >2 except for nausea or
vomiting until G1 or complete recovery. If chemother-
apy was delayed more than 3 weeks, the patient was
withdrawn. This phase II trial was planned using
Simon’s Statistical Single Stage Design. For sample size
calculation power was assumed as 80% and type I error
(alpha) as 5%. A CR rate of 70% or smaller was consid-
ered unacceptable, whereas a response rate of 90% or
greater was considered sufficient to justify further inves-
tigations. The single-stage design required the enrol-
ment of 28 patients; in cases of 24 responses or more
the regimen would be considered worthy of further
investigations. Descriptive statistics were provided either
by median and range for continuous variables or fre-
quency for categorical variables. Response rates and
toxicities were summarised by the 95% confidence inter-
val; interval estimation was provided by the Wilson
formulae [5]. Disease-free survival was estimated from
the end of chemo-radiotherapy (or date of colostomy
when done) to relapse, death or last known follow-up.
Overall survival was estimated from the start-time of
chemo-radiotherapy to death or last known follow-up.
The Kaplan-Meier approach was used for the probability
estimation. All analyses were carried out using SAS sta-
tistical software (SAS Institute, Cary, NC).
Results
Patient characteristics
From June 1999 to June 2008, 29 patients were consid-
ered eligible for the study. Main patient characteristics
were described in Table 1: stage II 9 patients (8 T2/N0
and 1 T3/N0), stage III A 14 patients (1 T1/N1, 4 T2/
N1, 6 T3/N1, 3 T4/N0) stage IIIB 6 patients (1 T1/N3,
1 T4/N1, 1 T4/N2, 3 T4/N3). All patients completed
chemo-radiotherapy and were considered evaluable for
response. Median duration of CT-RT was 11 weeks
(8-17), with a median length of external RT of 49 days
Table 1 Patients’ Characteristics
Variables Number
Median age (yrs) 57 (range 40-75)
Gender
Males 4 (14%)
Females 25 (86%)
Grading
G1 1 (3%)
G2 13 (45%)
G3 8 (28%)
Unknown 7 (24.1%)
Performance status (ECOG)
0 20 (71%)
1 7 (25%)
2 1 (4%)
Concomitant Pathologies 15 (52%)
Clinical staging
T1N1 1 (3%)
T1N3 1 (3%)
T2N0 8 (28%)
T2N1 4 (14%)
T3N0 1 (3%)
T3N1 6 (21%)
T4N0 3 (10%)
T4N1 1 (3%)
T4N2 1 (3%)
T4N3 3 (10%)
Tumor location
Anal canal 20 (71%)
Anal canal + anal margin 8 (28%)
Anal margin 1 (3%)
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am e d i a nd o s eo f4 1 . 4G y( r a n g e3 6 . 0 - 4 6 . 8 )t h r o u g h
external RT, while the primary tumor and involved
nodes received a median dose of 59.4 Gy (range 54.4-74
Gy), either using external RT alone or combined with
BRT. With regard to BRT, a median dose of 15 Gy
(range 4-30 Gy) on primary tumor was given to 12
patients after a median interval from the end of RT of
3.2 weeks (range 0.1-5.6). Nine of them were treated by
H i g hD o s eR a t e / P u l s e dD o s eR a t et e c h n i q u eb yu s i n ga
cylindrical applicator while in 3 patients, interstitial
implant of BRT was performed under anaesthesia with a
perineal template. Total median RT dose in patients
with Stage T1 was 59.4 Gy (range 59.4-59.4); T2 62.8
(range 54.4-74); T3 59.4 (56.4-69); T4 59.4 (59,4-70.4).
Stage T2 received a larger total dose compared to more
advanced tumours: this can be explained by the more
frequent use of BRT boost which increases total dose.
Treatment Response
Two months after the end of chemoradiotherapy, in 27
out of 29 patients (93.1%; 95% CI: 78% - 98%) CR was
documented, while in two patients a stable disease (SD)
was reported. One of them presented CR at subsequent
tumor assessment, 3 months later and the other pro-
gressed after few months. Two patients were diverted
pre-treatment due to local disease extension and one of
them underwent successful reversal after nine months
from the end of RT; in the remaining one, persistent
anal sphincter incontinence was observed. During treat-
ment in one case colostomy was considered due to sub-
occlusion determined by treatment-related congestive
tumour response. After chemoradiotherapy two patients
underwent abdominal perineal resection for local disease
persistence, but in one case no residual tumour was
documented in the surgical specimen. The rate of
colostomy was 14%. The 1-year and the estimated
7-year colostomy-free survival were 85.9% (C.I. 73.1% -
98.7%). Over time three patients with CR, exhibited sys-
temic relapse at 4 and 34 months. One patient died and
the other is still alive at 19 months since evidence of
relapse. After a median follow up of 42 months (range:
4-81), 25 patients are still alive without relapse, 1 patient
is alive with relapse and 3 patients died due to PD. The
estimated 3, 5 and 7-year DFS were 83.4% (C.I. 68.3%-
98.5%) and the estimated 3-year OS was 92.3 (range
82%-100%) and 5 and 7-year OS were 85.7% (C.I. 70% -
100%) (Figure 1; Figure 2).
Figure 1 3- 5- and 7-years Disease-Free Survival.
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evidence of disease, was censored at the date of
colostomy.
Delivered Treatment and Toxicity
During treatment 14 patients discontinued chemora-
diotherapy due to RT side effects, which lasted with as
median 9 days (range 1-39) (Table 2). No chemotherapy
delay more than 3 weeks was observed. At the 2
nd
month, 11 patients reported toxicities mostly related to
RT; two events were classified as G3-G4 (1 proctitis and
1 rectal bleeding). Concerning chemotherapy a total of
98 cycles were administered: FU was given in 97, while
C was given in 94. (Table 3) FU and C were given
together in 93 courses and in 62 without delays/modifi-
cations; in 4 cases and 1, FU and C were given as single
agent, respectively. All patients received at least 2 cycles
of C: 5 patients (17.2%) received two cycles, 12 patients
(41.4%) three and 12 patients (41.4%) four cycles. The
rate of patients who performed 4 cycles was 21.4%
among T1/T2; 57.1% among T3 and 62.5% among T4
stage. In 70 cycles out of 94 (74.5%) CT full dose-inten-
sity was administered.
Focusing on the first two mandatory cycles, 20
patients out of 29 received a full-intensity dose while in
9 patients the 2
nd cycle was delayed or modified due to
1 G3 neutropenia and 2 G1-2 leucopoenia, 6 G2-G3
non-haematological toxicities. At 6 months after the end
of RT, 6 patients did not exhibit any treatment related
toxicity. Most frequent late events G3-G4 occurred in
14 patients: proctitis (5), dermatitis (4) bladder dysfunc-
tions (2), sexual dysfunctions (9), low extremities venous
thromboses (2), dysuria (1), stenosis (1) and tenesmus
(1). Five patients reported G1 leucopoenia (Table 4).
Discussion
Concurrent chemoradiotherapy is the standard treat-
ment for localized anal cancer, while surgical resection
has been reserved as salvage strategy only for persistent
disease and for local relapse. However, it often fails to
control spread of the disease. With M and FU contain-
ing CT-RT 60-90% local control rates and 60-70%
5-year survival rates were reported, with infrequent need
for colostomy [1,6,7].
Mitomycin added to FU shows improved results in
terms of local control and time to colostomy in 3
Figure 2 3- 5- and 7-years Overall Survival.
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FU as single agent [2,8,9]. Unfortunately M can cause
severe, life-threatening haematological adverse events
(18%), lung toxicity, and haemolytic-uremic syndrome.
Alternative regimens containing C, cytotoxic agent
with considerable interest as a radiation sensitizer, have
been investigated in phase II trials, even if no definite
role of this agent is well determined by now (Table 5)
[6,10-13].
In our phase II trial the role of early C-containing che-
motherapy and concurrent radiotherapy followed by the
same regimen administered for one or two courses, was
investigated in order not to delay RT, considered as an
irreplaceable therapeutic procedure in the treatment of
anal SCC and in order to evaluate additional therapy in
high risk cases. In this population of patients, 93.1%;
(95% CI: 78% - 98%) of CR was reported at 2 months
with an estimated DFS of 83.4% (68.3%-98.5%) and esti-
mated 7-years OS of 85.7% (70% - 100%). These data
confirm the efficacy of C-containing schemes as
previously reported in phase II trials. The results of our
study might be related to better radiosensitizer action of
FU administered as continuous infusion and to tailored
consolidation CT courses delivered in cases of high risk
baseline stage and ‘slow response’ after concomitant
chemo-radiotherapy. As for colostomy on 27 evaluable
patients (two patients had colostomy before treatment), 3
patients (11%) derived during or after chemo-radiother-
apy. Concerning acute toxicity, we observed perineal
mucosa and skin side effects of grade 3-4 in about 40% of
patients, similar to previously reported literature data
(Table 4). Grade 3-4 diarrhoea was observed in less than
5% of patients, with a lower incidence compared to that
reported by older series (30-44%) [9,14,15]. The modern
use of 3D conformal RT with optimized protection of
normal tissues, the technique of shrinking fields, and
Table 2 RT on-treatment toxicity
Variables Number
29
No of patients with at least 1 toxicity 29 (100%)
Maximum grade toxicity
G2 16
G3 12
G4 1
No of side effects 95
G1 17
G2 63
G3 14
G4 1
No. of patients with gastrointestinal toxicity 26 (89.7%)
No. of GI side effects 49
Abdominal pain 5 (2)*
Diarrhoea 14 (1)*
Mucorrhea 6
Nausea/vomiting 6
Proctitis 6
Rectal bleeding 2
Rectal pain 4
Constipation 2
Tenesmus 4
No. of patients with genito-urinary toxicity 10 (37.9%)
No. of GU side effects 11
Dysuria 11
No. of patients with other toxicities 26 (37.9%)
No. of Other toxicities 35
Dermatitis 25 (9)*
Mucositis 10 (3)*
*In parentheses the number of G3-G4 events.
Table 3 Chemotherapy characteristics and on-treatment
toxicities
Variables Number
Total number of cycles 98
Fluorouracil 97^
Cisplatin 94*
Patients receiving
2 cycles 5
(17.2%)
3 cycles 12
(41.4%)
4 cycles 12
(41.4%)
Cisplatin modification (total # of cycles = 94)
Full dose-intensity 70
(74.5%)
Delay/modification 24
Cisplatin and/or Fluorouracil modification (total # of cycles
over the first 2 cycles = 58)
Full dose-intensity 49
(70.7%)
Delay/modification 9
Reasons
Haematological toxicities 2
Neutropenia (G3) 1
Leucopoenia (G1) 1
Non Haematological toxicities 5
Diarrhoea (G2) 1
Nausea (G2 and G3) 2
Nausea and Diarrhoea (G2) 1
Mucositis (G2) 1
Haematological and non-haematological toxicities 1
Diarrhoea (G2) and Leucopoenia (G2) 1
Other toxicities 1
Hypoacusia (G2) 1
^1 patient received C only.
*5 patients received Fluorouracil only.
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bute to reduce these side effects [15,16]. The literature-
reported rate of late toxicity, varies from 4% to 50%
depending on follow-up length, radiation treatment para-
meters such as RT technique and fraction site, and
chemotherapeutic agents combination [17]. In our series
23 patients had at least one G2, while 15 at least one G3-
G4 late toxicity. The highest toxicity rate was the rectal
one (16 patients), with G3 reported in 5 patients. Among
other G3-G4 toxicity, we observed 10 cases of sexual dys-
function (9 F and 1 M), 5 anal ulceration, 4 dermatitis, 3
urinary events, 1 vulvo-vaginitis, 1 bone fracture. Toxic
late events reported in our series seem to be similar to
previous reported literature data, except for sexual dis-
comfort which was often not described [6,10-12]. Intraca-
vitary or interstitial RT was used to deliver a boost to the
tumor bed, while sparing surrounding normal structures.
The incidence of G≥2 late side effects was higher in
patients receiving a boost with external RT than those
receiving it by BRT: among the 12 BRT patients, 5
(41.7%) suffered from side effects higher than G2 as
maximum toxicity compared to 10 out of 17 patients
(58.8%) in external RT group. In particular, all the BRT
boost patients experienced a lower bladder toxicity
(8.3% vs. 41.2%, p 0.05) and a slight higher rectal toxi-
city (58.3 vs. 52.9, p 0.77) compared external RT boost
patients. In the BRT boost group, no relationship
between rectal maximum toxicity and total dose was
found, G ≥2 toxicity was observed in all 3 patients trea-
ted with interstitial modality and in 3 out of 9 patients
treated with intracavitary modality.
Table 4 Late toxicity
Number of Events
Variables Grade 1-2 Grade 3 Grade 4
Dysuria/Incontinence 2/4 2/- -/1
Abdominal Pain 4 - -
Rectal Pain 4 1 -
Bleeding 10 - -
Ulceration - 3 1
Anorectal Stenosis - 1 -
Female Sexual Dysfunction 15 10 8
Male Sexual Dysfunction - 1 -
Deep Venous Thrombosis - 2 -
Bone Fracture - 1 -
Leucopoenia 5 - -
Table 5 Cisplatin-containing Phase II Trials
Author Trial, Total number
patients and Stage
Regimen Response Toxicity ≥ G3
Martenson, 1996 Phase II: 19 pts
T1-4/N0-3/M0
2 cycles FU 1000 mg/m2 × 4 days,
CDDP 75 mg/m2 concomitant to RT 59.4 Gy
15 CR (79%);
4 PR (21%)
Colostomy rate: na DFS: na
OS: na
G3-4:
haematological 50%
diarrhoea 20%
skin 20%
G5: 1 infection
Doci, 1996 Phase II:
35 pts
T1-T3/N1-3/M0
2-3 cycles
FU 750 mg/m2 × 4 days,
CDDP 100 mg/m2
concurrent RT 36-38 Gy
33 CR (94%)
2 PR (6%)
Median follow-up 37 mos.
colostomy free 86%
OS 94%
G3:
Diarrhoea 2-3%
skin 2-3%
Gerard, 1998 Phase II: 95 pts
T1-4/N0-3/M0
1 cycle FU 1000 mg/m2 × 4 days,
CDDP 25 mg/m2/d × 4 days concomitant
to RT followed by a boost with 192 Ir implant.
85 CR (89%)
7 PR (8%)
Median follow-up 64 mos.
5y colostomy free 71%
5yOS 84%
G3:
haematological 3%
TVP 1%
Peiffert, 2001 Phase II: 80 pts
T1-4/N0-3/M0
2 neoadjuvant and 2 cycles
FU 800 mg/m2 × 4 days,
CDDP 80 mg/m2
concomitant to RT 45 Gy
70 CR 70 (87%)
4 PR (5%)
At 3 year: colostomy-free 73%;
OS 86%
G3-G4:
angina pectoris 2%
mucositis 16%
diarrhoea 16%
skin 32%
G5: 1 TEP
Cho, 2008 Phase II: 31 pts
T1-4/N0-3/M0
2 cycles
FU 750-1000 mg/m2 days 1-5,
CDDP 75-100 mg/m2
concomitant to RT 45 Gy
®2 consolidation cycles FU +CDDP
31 CR (90.3%)
4 PR (9.7%)
Median follow-up 72 mths;
DFS 82.9%
OS 84.7%
G3-G4:
skin 55%
neutropenia 33%
infection 3.2%
fatigue 4.8%
Zampino, Current work Phase II:
29 pts
T1-4/N0-3/M0
2-4 cycles
FU 200 mg/m2 i.c
CDDP 75 mg/m2 day1/21
concomitant to RT 45-74 Gy
Median follow-up 7 yrs;
CR 93%
DFS 85%
OS 86%
G3-G4:
mucositis 10%
diarrhoea 3%
skin 31%
Hematological 3%
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investigated in phase III trials with the aim to evaluate
neoadjuvant treatment before concomitant chemora-
diotherapy [7,18-20]. In the Intergroup RTOG 98-11
phase III trial the comparison was evaluated between C
plus FU induction treatment followed by the same che-
motherapy and concurrent radiation and M plus FU and
concurrent radiation: C-based therapy failed to improve
disease-free-survival compared with M-control arm, and
resulted in a significantly worse colostomy rate (19% vs
10%); severe hematological toxicity was confirmed to be
worse with the M-containing arm [7].
It must be emphasized that the RTOG 98-11 trial was
not a pure comparison of concurrent chemoradiation with
C plus FU versus M plus FU but, rather, was a comparison
of one strategy versus another. The assumption that the
strategy of induction chemotherapy had been able to
reduce the bulk of local-regional anal SCC was not sup-
ported by the results documented in randomized study.
Also in the ACCORD 03 trial neoadjuvant role of C-FU
was investigated [19] Early data on quality of life has
already been published [20]. Combination of C and M was
also evaluated in a phase III trial and compared to conven-
tional FU-M concomitant to RT: local control was reported
in 89% vs 74%, respectively with acceptable toxicity [21].
At the moment these results do not support the use of
C-based neoadjuvant chemotherapy followed by che-
moradiotherapy in place of M in combination with FU
and radiotherapy in the treatment of anal canal
carcinoma.
Conclusions
The promising results obtained in present study even
though observed in a limited number of patients,
seemed to be suitable for future investigation with the
aim to confirm the possible use of early administered
C-containing treatment with radiotherapy and to evalu-
ate the advantage of sequential chemotherapy after che-
moradiotherapy in high risk patients with anal SCC.
Further research into molecular biology related to dis-
ease progression and resistance to chemoradiotherapy
may provide a better understanding of different pattern
of anal carcinoma and may also support the clinical use
of biologic agents. Future investigations will be directed
towards the evaluation of new cytotoxic agents such as
taxanes or targeted drugs such as anti-epidermal growth
factor receptor, concomitant to RT and to determining
the role of intensity-modulated radiotherapy [22,23].
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